Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | STAT1 | P42224 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497349 | 0.87 | POLB (0.44) | POLBMEN1KMT2AHDAC1NPC1 | |
| SCHEMBL2491560 | 0.82 | POLB (0.33) | POLBMEN1KMT2AHDAC1 | |
| SCHEMBL2497337 | 0.82 | POLB (0.33) | POLBMEN1KMT2AHDAC1 | |
| SCHEMBL2497340 | 0.81 | DPP4 (0.47) | POLBMEN1KMT2AHDAC1NPC1 | |
| SCHEMBL2497450 | 0.79 | POLB (0.33) | POLB | |
| SCHEMBL2491533 | 0.78 | HDAC1 (0.41) | POLBMEN1KMT2AHDAC1NPC1 | |
| SCHEMBL2492543 | 0.77 | POLB (0.38) | POLBMEN1KMT2AHDAC1 | |
| SCHEMBL2497452 | 0.76 | POLB (0.33) | POLB | |
| SCHEMBL12191786 | 0.73 | KDM4E (0.37) | POLBMEN1KMT2AHDAC1 | |
| SCHEMBL12191787 | 0.73 | POLB (0.37) | POLBMEN1KMT2AHDAC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882694-B1 | OLIGOMERS AND POLYMERS OF THIOPHENE COMPOUNDS HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL IND LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8030438-B2 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030438-B2 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1882694-A1 | THIOPHENE COMPOUND HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | RRP12, NR2E1, TST | POLB 1838/4885MEN1 4275/4885KMT2A 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.